secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001140361-23-050844
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire appoints George Magrath as CEO effective Nov 1; awards 1M equity shares
--------------------------------------------------------------------------------

- Dr. George Magrath appointed CEO and board member, effective Nov 1, 2023; succeeds interim CEO Rick Rodgers who remains on board.
- Employment agreement: $575,000 base salary, 55% target bonus, 600,000 stock options and 400,000 RSUs as inducement grants.
- Inducement plan increased by 2,000,000 shares to total 2,325,258 shares available for equity awards.
- Magrath previously CEO of Lexitas Pharmaceutical Services; led acquisition and growth in ophthalmic CRO.
- Committee composition changed effective Nov 15: Cam Gallagher chairs audit, James Manuso chairs compensation, Richard Rodgers chairs nominating.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123050844/0001140361-23-050844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123050844/ef20013742_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-050844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer